Twitxy Saved

MSKHemOncTrials

@MSKHemOncTrials

Info on clinical trials @MSKCancerCenter. Unmonitored feed. Call us: Leukemia 212-639-5279/ Lymphoma 646-497-9137/ Myeloma 646-497-9062/ BMT 877-836-ABMT
New York, NY twitter.com/MSKHemOncTrials Joined August 2013
927 Following 1.6K Followers 14K Posts

Latest posts 5

MSKHemOncTrials @MSKHemOncTrials
Thanks for highlighting this @MSKCancerCenter study by @LandauHeather #bmtsm #mmsm
A pilot trial of homebound hematopoietic cell transplantation found that it is safe and feasible to deliver autologous hematopoietic cell transplantation care in a homebound setting. Read the full article: ow.ly/jj6v50M7o8s #openaccess
View quoted post on X
0 replies 1 reposts 4 likes 1.5K views View on X
MSKHemOncTrials @MSKHemOncTrials
Interesting results in light of recent paper by @MSKCancerCenter @AnaAlarconTomas @joshuaafein @DrMiguelPerales @RShouval on outcomes in pts treated for relapse after #CARTcells #ASH22 #lymsm ncbi.nlm.nih.gov/pubmed/36335261
Eddie Cliff @Eddie_Cliff Dec 11, 2022
French DES-CAR-T study of pts w post-CAR-T DLBCL relapse
Best responses with bispecific antibodies (ORR 37.5%, survival out to a year)
Also some promising responses in "targeted therapy" heterogeneous group (see slide)
Lenalidomide responses underwhelming
#lymsm #ASH22 #TCellRx
View quoted post on X
MSKHemOncTrials @MSKHemOncTrials
Check out new study in @BloodAdvances from @MSKCancerCenter BMT Service @mariamtn89 @MScordoMD @DrMiguelPerales @MSanchezEscamil & colleagues #bmtsm
Blood Advances @BloodAdvances Dec 1, 2022
Compared with pre-HCT, post-HCT dynamic EASIX scores may better predict NRM as patients acquire additional endothelial injury and toxicities. loom.ly/KD5vyJQ #clinicaltrialsandobservations #transplantation
View quoted post on X